International Medical Journal, Vol. 20., Iss. 3, 2014, P. 35−39.
Clinical features of ischemic stroke in patients with polymorphism of 5G/4G gene of type 1 plasminogen activator inhibitor
Bogomolets National Medical University, Ukraine
Institute of Biology, Taras Shevchenko National University, Kyiv, Ukraine
Clinical features of ischemic stroke in patients with polymorphism 5G/4G gene inhibitor of plasminogen activator 1. The aim of this study was to characterize neurological disorders in patients with ischemic stroke and polymorphism of 5G/4G PAI−1 gene, an important regulator of the fibrinolytic system. This clinical neurological and genetic study involved 113 patients (mean age 73.6±8.9 years) with acute ischemic stroke. Genotyping was performed using PCR−thermocycler "Eppendorf". Statistical analysis was performed using SPSS 17.0 and included one−way ANOVA and Pearson χ². When compared genotype frequencies of polymorphism 5G/4G PAI−1 gene in patients with ischemic stroke with the controls significant differences were not found. Fatal stroke in the first 14 days of the disease was reported in 17 (15 %) patients without significant differences between the groups (p = 0.12). The most favorable type of ischemic stroke course was reported in patients with genotype 5G/5G PAI−1 gene, they showed more complete recovery of neurological functions and on the 14th day of the stroke 34.8 % demonstrated complete resolution of neurological disorders and further 56.5 % showed mild neurological deficiency. Our findings demonstrate that polymorphism of 5G/4G PAI−1 gene is associated with clinical features of ischemic stroke. Patients with abnormal homozygous 4G/4G PAI−1 gene have more pronounced neurological deficiency during the first 14 days of the stroke, with a high mortality rate (21.3 %) and insufficient recovery of the neurological function by the end of the second week of ischemic stroke.
Key words: ischemic stroke, type 1 inhibitor of plasminogen activator, allelic polymorphism.